Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies ...

Heart disease and breast cancer are two of the most significant health threats facing Black women today. Here's ...

Bruce Cozadd, the retiring CEO of Jazz Pharmaceuticals, has outlined a developing oncology pipeline at the company. Speaking ...

The firm aims to advance two breast cancer therapies in HR-positive, HER2-negative advanced breast cancer this year.

OS Therapies shares Phase 2b trial results showing OST-HER2 improves survival rates in rare metastatic osteosarcoma, surpassing historical controls.

Linda Nolan, 65, passed away after a 20-year breast cancer battle. She was first diagnosed with stage-three breast cancer in ...

OS Therapies shares surged Wednesday after the biotech company reported positive data from a clinical trial for its cancer treatment OST-HER2. Shares of the N.Y., clinical-stage biotechnology company ...

The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...